The approval is supported by a combination of current clinical data and model-informed drug development techniques.

The FDA has approved risperidone once-monthly, extended-release injectable suspension for maintenance treatment of bipolar I ...

Teva Pharmaceuticals' Uzedy therapy to treat bipolar I disorder received approval from the Food and Drug Administration. The biopharmaceutical company said Friday the therapy was approved as a ...

On World Mental Health Day, this writer narrates her story of struggling with bipolar disorder, an illness that has ...

Teva Pharmaceutical Industries Limited TEVA recently announced that the FDA has approved expanded use of its branded product, ...

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive ...

Bipolar disorder comes in many distinct forms and genetic differences cause people to respond differently to lithium, paving ...

Bipolar disorder treatment often includes some combination of medications like mood stabilizers and antidepressants alongside therapy.

Paris: The FDA has approved UZEDY, the first subcutaneous long-acting risperidone formulation utilizing SteadyTeq™ technology ...

This is a developing news story. Please check back soon for updates. The FDA approved extended-release Uzedy for the ...

World Mental Health Day 2025 is an opportunity to raise awareness about mental health conditions like bipolar disorder that ...

YouTube has become a favorite platform for many people with mental health problems. It is a place where they can share their ...